Sorry, you need to enable JavaScript to visit this website.

Study to Provide Access to Palbociclib and Letrozole For Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Breast Cancer That has Spread to Other Parts of the Body

Study of Palbociclib in Combination with Letrozole as Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer for Whom Letrozole Therapy is Deemed Appropriate

Category & Conditions: Cancer
Medicine: IBRANCE®(PALBOCICLIB)
ClinicalTrials.gov Identifier (NCT): NCT02600923
Protocol ID: A5481053
PrintDownload
Open Plain Language Summary Result: Click here